Premium
Haemodialysis outcomes of Aboriginal and Torres Strait Islander patients of remote Kimberley region origin
Author(s) -
Marley Julia V,
Dent Hannah K,
Wearne Maree,
Fitzclarence Cherelle,
Nelson Carmel,
Siu Karen,
Warr Kevin,
Atkinson David
Publication year - 2010
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.2010.tb04035.x
Subject(s) - indigenous , medicine , referral , pacific islanders , northern territory , demography , retrospective cohort study , mortality rate , family medicine , ethnology , population , environmental health , history , ecology , sociology , biology
Objectives: To compare the clinical outcomes and mortality rates of Aboriginal and Torres Strait Islander people of Kimberley origin receiving haemodialysis (HD) treatment with other subsets of Aboriginal and Torres Strait Islander HD patients (Northern Territory, Western Australia excluding the Kimberley region, the rest of Australia) and Australian non‐Indigenous HD patients. Design, participants and setting: Retrospective identification of Aboriginal and Torres Strait Islander patients of Kimberley origin and analysis of secondary data from the Australia and New Zealand Dialysis and Transplant Registry; this group was compared with other Australian patients receiving HD treatment from 1 January 2003 to 31 December 2007. Main outcome measures: Clinical outcome measures; comorbid conditions; death rates per 100 patient‐years, unadjusted and adjusted (for age, sex, comorbid conditions, late referral to nephrologist treatment). Results: Seventy per cent of HD treatments for Aboriginal and Torres Strait Islander patients of Kimberley origin was provided in the Kimberley. They had comparable adjusted mortality rates to non‐Indigenous Australian patients (adjusted mortality rate ratio, 0.80; 95% CI, 0.51–1.23). Conclusions: This is the first report showing similar mortality rates for Aboriginal and Torres Strait Islander people exclusively from a remote area of Australia and non‐Indigenous Australians receiving HD treatment. HD treatment delivered closer to home can be safe and effective in remote areas.